SCHEMBL2208159

SCHEMBL2208159

CNC1CN(C(=O)OC(C)(C)C)CCn2c1nc(C(=O)NCc1ccc(F)c(C)c1)c(O)c2=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.45
CYP2C9 P11712 1/20 0.45
TRPV3 Q8NET8 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 1/20 0.38
TP53 P04637 3/20 0.38
LMNA P02545 1/20 0.37
MMP13 P45452 2/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
METTL3 Q86U44 1/20 0.37
S1PR3 Q99500 1/20 0.36
EED O75530 1/20 0.36
RBBP4 Q09028 1/20 0.36
SUZ12 Q15022 1/20 0.36
EZH2 Q15910 1/20 0.36
AEBP2 Q6ZN18 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2204214 0.90 KCNH2 (0.42) KCNH2CYP2C9SMN1; SMN2MEN1CYP2C19
SCHEMBL2208259 0.86 CYP2C9 (0.58) KCNH2CYP2C9SMN1; SMN2MEN1CYP2C19
SCHEMBL13421765 0.80 KCNH2 (0.45) KCNH2CYP2C9TP53MMP13
SCHEMBL3375742 0.77 CYP2C9 (0.45) KCNH2CYP2C9MMP13
SCHEMBL2207925 0.77 CYP2C9 (0.55) KCNH2CYP2C9SMN1; SMN2MEN1CYP2C19
Hydrochloric Acid SCHEMBL3374123 0.77 CYP2C9 (0.45) KCNH2CYP2C9MMP13
SCHEMBL13917328 0.75 KCNH2 (0.47) KCNH2CYP2C9MMP13
SCHEMBL4397388 0.74 CYP2C9 (0.47) KCNH2CYP2C9SMN1; SMN2TP53LMNA
SCHEMBL2203798 0.74 CYP2C9 (0.63) KCNH2CYP2C9LMNAMMP13
SCHEMBL13405289 0.74 MMP13 (0.41) KCNH2CYP2C9MEN1CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257162-A1 HIV INTEGRASE INHIBITORS SUMMA VINCENZO 2011-10-20 US disclosed
US-7981879-B2 HIV integrase inhibitors Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) 2011-07-19 US disclosed
US-20090253681-A1 HIV Integrase Inhibitors MSD ITALIA S.R.L. (IT) 2009-10-08 US disclosed
EP-1866313-A1 HIV INTEGRASE INHIBITORS Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2007-12-19 EP disclosed
WO-2006103399-A1 HIV INTEGRASE INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257162-A1 HIV INTEGRASE INHIBITORS REV1, CDK9, INTS9 KCNH2 2918/4885CYP2C9 672/4885TRPV3 4752/4885
US-20090253681-A1 HIV Integrase Inhibitors REV1, INTS9, H1-10 KCNH2 3625/4885CYP2C9 449/4885TRPV3 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.